Treating pain with novel non-opioid based drugs

Data-driven treatments for patients in need.

About Alyea Therapeutics

A biotechnology company dedicated to developing non-opioid pain relief solutions, Alyea Therapeutics focuses on Complex Regional Pain Syndrome (CRPS) and other chronic pain conditions.

Spearheaded by Dr. Amol Soin, Alyea intends to transform pain management through innovation. Alyea’s proprietary lead product and key offering, Low Dose Naltrexone (LDN), will be entering late-stage clinical trials, significantly holding FDA orphan drug designation. Orphan status offers such benefits as market exclusivity, tax credits, and streamlined regulatory support. Alyea Therapeutics is a wholly owned subsidiary of ALT 5 Sigma Corporation (Nasdaq:ALTS) with plans to be spun out in the first half of 2025 as its own stand alone public company.

The Opioid Issue

Chronic Pain
20.9%

Nearly 20.9% of U.S. adults (51.6 million people) experience chronic pain, according to the U.S. Centers for Disease Control and Prevention (CDC).

Fatal Overdoses
108,000

The CDC estimates more than 108,000 drug overdose deaths occur each year.

Synthetic Opioids
87%

Synthetic opioids were involved in an estimated 87% of opioid and 65% of all drug overdose deaths.

Revolutionizing Pain Management

Alyea’s goal is revolutionizing pain management by advancing innovative solutions for the effective treatment of Complex Regional Pain Syndrome (CRPS). Our mission is improving the quality of life for patients globally and we are committed to innovative science.

Dr. Amol Soin, one of America's top doctors

Alyea’s leader, Amol Soin, MD, head of the Soin Medical Centre and Research Lab, has been recognized multiple times as one of America's top doctors. He received the Patient's Choice Award, an honor given only to the top 1% of the country’s physicians. Board certified in anesthesiology and pain medicine and a fellow of interventional pain management at the World Institute of Pain, he served as a pain management fellow at the Cleveland Clinic, the oldest and largest academic pain management department in the United States. He was instrumental in passing statewide rules and guidelines to combat the opioid crisis.

Alyea Solutions

Pharma’s Holy Grail
Non-opioid based pain medication with proven safety is Pharma’s Holy Grail. Alyea is now guiding Low Dose Naltrexone through FDA clinical trials, obtaining necessary approvals, all with the goal of bringing the novel drug to market and providing relief to those who suffer from CRPS.
Low Dose Naltrexone (LDN)
Clear Patch Technology
An additional revenue pipeline, Clear Patch Technology is an advanced topical drug delivery system also designed to provide customizable pain relief. Patients can apply the patch directly to affected areas, where it administers a controlled dose with a targeted mechanism of action.
The Alyea Clear Patch

Investors

For more information about Alyea Therapeutics and its novel drug therapy, please click here.

Get in Touch